Compare IDE & CUE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | IDE | CUE |
|---|---|---|
| Founded | 2010 | 2014 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Finance/Investors Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 200.8M | 233.5M |
| IPO Year | N/A | 2017 |
| Metric | IDE | CUE |
|---|---|---|
| Price | $13.22 | $28.16 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $120.00 |
| AVG Volume (30 Days) | 37.9K | ★ 195.4K |
| Earning Date | 01-01-0001 | 05-13-2026 |
| Dividend Yield | ★ 8.83% | N/A |
| EPS Growth | N/A | ★ 61.11 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $27,466,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 195.75 |
| 52 Week Low | $11.36 | $0.17 |
| 52 Week High | $14.30 | $45.50 |
| Indicator | IDE | CUE |
|---|---|---|
| Relative Strength Index (RSI) | 46.71 | 49.86 |
| Support Level | $13.05 | $24.70 |
| Resistance Level | $13.46 | $33.95 |
| Average True Range (ATR) | 0.13 | 3.81 |
| MACD | 0.02 | 0.01 |
| Stochastic Oscillator | 53.85 | 43.59 |
Voya Infrastructure, Industrials and Materials Fund is a diversified closed-end management investment company. The primary objective of this investment fund is to achieve total return by combining current income, capital gains, and capital appreciation. To achieve this objective, the fund invests in companies that own and/or operate infrastructure facilities in the infrastructure sector, as well as in a broad range of companies in the industrials and materials sectors that the Sub-Adviser believes will benefit from infrastructure building, renovation, expansion, and utilization.
Cue Biopharma Inc is a clinical-stage therapeutics company focused on advancing a robust portfolio of potentially transformative therapies aimed at enabling functional cures across immunological disorders. Its product pipeline includes CUE-221, an anti-IgE antibody candidate being developed for allergic diseases. The company has also developed the Immuno-STAT platform for targeting disease-related T cells and is developing CUE-401, an IL-2 and TGF-B therapeutic candidate for autoimmune diseases.